Carpal tunnel syndrome

Global Orthopedic Braces & Supports Market Report 2022: Industry Expected to Reach $5.1 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Medical Devices, Health, CAGR, FDA, Obesity, Sport, Injury, PCL, Leg, Brace, Pain management, Osteoarthritis, Trauma, Elective surgery, ACL, Bone, Medial knee injuries, Marketing, Carpal tunnel syndrome, DJO, Surgeon, Acquisition, Partnership, Posterior cruciate ligament, Standard of care, Incidence, Tendinopathy, Patient, Rupture, DJO Global, Awareness, Diabetes, Essity, Anterior cruciate ligament, Risk, Medical device, Sports equipment, Dentistry

The Global Orthopedic Braces & Supports Market size is expected to reach $5.1 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Orthopedic Braces & Supports Market size is expected to reach $5.1 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Orthopedic braces and supports provide various advantages over traditional goods, including lower cost, improved efficacy, more patient comfort, and ease of use.
  • The rising number of leg and knee injuries has resulted in a jump in sales of knee braces and supports.
  • Knee braces and supports are used to treat ailments such as sprained medial knee ligaments, anterior cruciate ligament (ACL) rupture, and posterior cruciate ligament (PCL) rupture after surgery.

National Safety Council, Amazon and Top Industry Employers Pledge to Reduce Workplace Injuries by 25% by 2025

Retrieved on: 
Thursday, June 2, 2022
MSD, Benchmark, Workplace, Commit, Injury, Predatory publishing, Advisory Council, Program, National Safety Council, Research, Safety, LLC, ESG, Lists of diseases, CEO, Carpal tunnel syndrome, Partnership, Organization, American Industrial Hygiene Association, Volunteering, Solution, Meteorite, University, Natural language processing, LAUNCH (Innovation Challenge), Student, Small business, Risk, Health, NASDAQ, AMZN, AMP, Innovation, Tendinopathy, The Chartered Institute of Ergonomics and Human Factors, Culture, NSC, MEGA, National Safety Month, Color, Index, Council, Cummins, Logging, Risk management, Personal protective equipment, Pharmaceutical industry, United, Tenneco, Amentum, Amazon, United Airlines

WASHINGTON, June 2, 2022 /PRNewswire/ -- Kicking off National Safety Month, and one year after announcing a historic partnership with Amazon (NASDAQ: AMZN), the National Safety Council (NSC) unveiled the first-of-its-kind MSD Pledge to reduce the most common workplace injury, musculoskeletal disorders (MSDs). Today, during the inaugural Workplace Safety Summit: Business Action to Prevent Musculoskeletal Injuries, more than 15 of the nation's leading organizations joined this effort and signed the pledge to improve workplace safety, reduce MSD risk, and enhance all workers' well-being.

Key Points: 
  • Today, during the inaugural Workplace Safety Summit: Business Action to Prevent Musculoskeletal Injuries, more than 15 of the nation's leading organizations joined this effort and signed the pledge to improve workplace safety, reduce MSD risk, and enhance all workers' well-being.
  • The MSD Pledge seeks to create safer outcomes for millions of workers worldwide by reducing these injuries by 25% by 2025.
  • Organizations signing the MSD Pledge promise to:
    Reduce risks by analyzing the causes of MSD injuries across operations and investing in solutions and practices that reduce risks to workers.
  • The National Safety Council is America's leading nonprofit safety advocate and has been for over 100 years.

Group Fitness Leader MOSSA Launches “De-Desk Your Body”

Retrieved on: 
Monday, May 23, 2022
Other Sports, Women, General Sports, Sports, Seniors, Fitness & Nutrition, Men, Health, Consumer, Risk, History, VP, Sitting, Pains, Music, Spencer Brown (rugby union, born 1973), University of Utah School of Medicine, ACHES, Research, Gustav-Adolf Mossa, Carpal tunnel syndrome, Movement, Life, Tightness, Microdeletion syndrome, Neck, University, YMCA, Back pain, CDC, Center, Death, Korea Disease Control and Prevention Agency, Furniture

MOSSA , the developers of group fitness programs that have inspired millions to move, announces the launch of De-Desk Your Body.

Key Points: 
  • MOSSA , the developers of group fitness programs that have inspired millions to move, announces the launch of De-Desk Your Body.
  • MOSSA On Demands De-Desk Your Body guides users through targeted movements that help reduce the soft tissue stiffness, tightness and soreness many people feel after sitting.
  • The MOSSA On Demand De-Desk Your Body sessions are only 5-7 minutes and can easily be incorporated into a busy schedule.
  • From early roots in successful health club ownership to pioneering the step fitness movement, MOSSA naturally evolved into one of the worlds preeminent developers of professional group fitness programs for health clubs, gyms, and YMCAs.

PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO

Retrieved on: 
Friday, May 13, 2022
Science, Health, Research, Medical Devices, Risk, AdvaMed, ResMed, Test, Harvard University, U.S. Securities and Exchange Commission, Nasdaq, Patient, IEEE Medal for Innovations in Healthcare Technology, Carpal tunnel syndrome, Mount Sinai Medical Center, COVID-19, Esophageal cancer, Research, Industry, Academic health science centre, Facebook, Time, Intention, YouTube, Instagram, Forward-looking statement, Communication, Technology, Organization, Faculty, Chief executive officer, Therapy, LinkedIn, Twitter, Security (finance), Harvard Medical School, Medtronic, Annual report, CEO, Pharmaceutical industry, Medical device, Physics, Lucid, Part Two

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage cancer prevention medical diagnostics company, today announced that PAVmed and Lucid Chairman & Chief Executive Officer Lishan Aklog, M.D.

Key Points: 
  • PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage cancer prevention medical diagnostics company, today announced that PAVmed and Lucid Chairman & Chief Executive Officer Lishan Aklog, M.D.
  • was selected as one of the Top 50 Healthcare Technology CEOs of 2022 by The Healthcare Technology Report .
  • The Healthcare Technology Report described this years awardees as some of the most cultivated, intelligent executives in the healthcare and technology industry.
  • Dr. Lishan Aklog is Chairman & CEO of PAVmed Inc. (Nasdaq: PAVM), a diversified, commercial-stage medical technology company which he co-founded, and its majority-owned subsidiary Lucid Diagnostics Inc., a cancer prevention medical diagnostics company (Nasdaq: LUCD).

PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit

Retrieved on: 
Thursday, April 28, 2022
Lucid, Intention, U.S. Securities and Exchange Commission, Carpal tunnel syndrome, LinkedIn, Time, Calendar, Class Action, YouTube, Nasdaq, Twitter, Settlement, Agreement, GLOBE, COVID-19, Court, Forward-looking statement, Company, Justice Center, Annual report, Security (finance), Lis pendens, Compromise, Communication, Research, Facebook, Eastern Time Zone, Risk, Hearing, Instagram, Esophageal cancer, Pharmaceutical industry, Risk management, Part Two

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit.

Key Points: 
  • NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a diversified commercial-stage medical technology company, today announced a procedural update on its settlement of a previously disclosed class action lawsuit.
  • As previously disclosed, on January 28, 2021, the Company entered into a term sheet agreement for the settlement of a previously disclosed putative class action lawsuit commenced in November 2020, captioned Spritzer v. PAVmed Inc., et al., C.A.
  • The terms of the settlement do not contemplate payment by the Company of any monetary damages.
  • PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics and digital health sectors.

SONEX HEALTH ANNOUNCES FULL MARKET RELEASE OF ULTRAGUIDETFR™ TO TREAT TRIGGER FINGER

Retrieved on: 
Wednesday, April 27, 2022
Trigger, Essentia, Patient, Syndrome, A1, Mayo Clinic, Essentia Health, Health, Finger, Anatomy, Nerve, SSM Health, Sonex Aircraft, Safety, Carpal tunnel syndrome, TFR, Physician, Suture, Institute, Ascending limb of loop of Henle, Medical imaging, Medical device, Health insurance

EAGAN, Minn., April 27, 2022 /PRNewswire/ -- Sonex Health today announced the full U.S. commercial launch of its UltraGuideTFR device, which is used in conjunction with real-time ultrasound guidance to perform trigger finger release (TFR) procedures.

Key Points: 
  • EAGAN, Minn., April 27, 2022 /PRNewswire/ -- Sonex Health today announced the full U.S. commercial launch of its UltraGuideTFR device, which is used in conjunction with real-time ultrasound guidance to perform trigger finger release (TFR) procedures.
  • "The full launch of UltraGuideTFR enables us to offer more clinicians safe and effective ways to treat common painful upper extremity conditions using minimally invasive techniques," said Sonex Health CEO Bob Paulson.
  • UltraGuideTFR is indicated for the treatment of trigger finger and is designed to incise the tendon sheath and A1 pulley through a single incision.
  • Sonex Health's second proprietary technology is UltraGuideTFR, for the treatment of trigger finger, also known as stenosis tenosynovitis.

PAVmed to Hold a Business Update Conference Call on May 12, 2022

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Health, Medical Devices, Carpal tunnel syndrome, U.S. Securities and Exchange Commission, COVID-19, Twitter, Security (finance), Research, Annual report, Intention, YouTube, Lucid, LinkedIn, Conference, Company, Nasdaq, Esophageal cancer, Communication, Webcast, Forward-looking statement, Instagram, Risk, Time, Risk management, Part Two, Facebook

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, at 4:30 PM EDT.

Key Points: 
  • PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, at 4:30 PM EDT.
  • , Chairman and Chief Executive Officer, will provide a business update including an overview of the Companys near-term milestones and growth strategy.
  • In addition, Dennis McGrath , PAVmeds Chief Financial Officer, will discuss the Companys first quarter 2022 financial results.
  • All listeners should provide the operator with the conference call name PAVmed, Inc. Business Update Conference Call to join.

Global Carpal Tunnel Syndrome Clinical Trials Market Research Study 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 13, 2022
General Health, Health, Other Health, Carpal tunnel syndrome, News, Decision-making, Trial, Clinical trial, Pharmaceutical industry

The "Carpal Tunnel Syndrome - Global Clinical Trials Review, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Carpal Tunnel Syndrome - Global Clinical Trials Review, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report provides an overview of Carpal Tunnel Syndrome Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Carpal Tunnel Syndrome.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

HSS Study Reveals Why Men are More Likely to Be Offered Surgery for Carpal Tunnel Syndrome

Retrieved on: 
Tuesday, March 22, 2022
Magnet, Hospital Records, Electrodiagnostic medicine, Research, Hip, Hypoesthesia, Arthritis, U.S. News & World Report, Education, Hispanic, Record, Diagnosis, Nursing, Wrist, Laboratory, Median nerve, Weill Cornell Medicine, Surgeon, Male, Electromyography, Ligament, Rheumatology, Therapy, EMG, HSS, Multimedia, Ascending limb of loop of Henle, Man, American Nurses Credentialing Center, Hand, Finger, Rheumatoid arthritis, Health, Inflammation, Muscle, American Academy, Weakness, Carpal tunnel syndrome, Trauma, Awareness, Black, Patient, Infection, Tendon, Organization, News, Orthopedic surgery, The Hospital, Thumb, Hospital, Hospital for Special Surgery, Lupus, Long Island, Physician, Arm, Elective surgery, Medical device, Medicine, MD, Newsweek

"Our study aimed to investigate if disparities in treatment for carpal tunnel syndrome exist," said Duretti Fufa, MD , HSS hand and upper extremity surgeon and senior author of the study.

Key Points: 
  • "Our study aimed to investigate if disparities in treatment for carpal tunnel syndrome exist," said Duretti Fufa, MD , HSS hand and upper extremity surgeon and senior author of the study.
  • Patients with severe symptoms are often offered carpal tunnel release , a minimally invasive surgical procedure that relieves pressure on the median nerve by cutting the carpal ligament.
  • For the study, Dr. Fufa and colleagues reviewed hospital records for 949 patients with carpal tunnel syndrome treated at HSS between February 2016 and October 2020.
  • "Overall, our findings suggest that increased utilization by males was largely explained by the fact that men were more likely to present with more severe carpal tunnel syndrome," Dr. Fufa said.

PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System

Retrieved on: 
Thursday, March 17, 2022
Science, Biotechnology, Research, Oncology, General Health, Health, Medical Devices, Clinical Trials, Risk, Esophageal cancer, LinkedIn, Carpal tunnel syndrome, Trial of the century, Forward-looking statement, Patient, Skin, IRB, Lucid, Bone marrow, Vein, Research, U.S. Securities and Exchange Commission, Communication, Security (finance), FIH, Coagulopathy, Dissection, Twitter, Intention, Time, Nasdaq, COVID-19, Radiology, Physician, Facebook, YouTube, Kidney, Maintenance, Annual report, Instagram, Infection, Medical imaging, Part Two, Cervix

All patients have also undergone successful infusion of fluids consistent with the study protocol and the devices intended use.

Key Points: 
  • All patients have also undergone successful infusion of fluids consistent with the study protocol and the devices intended use.
  • PortIO implantation was technically straightforward and well-tolerated by the patients, as was its use for infusions of fluid.
  • We look forward to completing this FIH study to demonstrate that PortIO can serve as such a maintenance-free long-term vascular access device.
  • The PortIO Intraosseous Infusion System consists of an implantable intraosseous vascular access device and insertion kit.